Solid Solution Lipid Compositions for Cardiovascular Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases associated with high lipid and/or lipoprotein levels are inadequate, as existing therapies like statins and fibrates have limitations such as not reducing triglyceride levels effectively and causing significant side effects when used in combination.
Innovation Solution
Development of solid solution pharmaceutical compositions that incorporate therapeutic compounds with room temperature solid and liquid lipids, stabilizing agents, and neutralizing agents to create a lipid-adjuvant delivery system that effectively modulates lipid and lipoprotein levels, targeting macrophages and dendritic cells for improved cardiovascular disease treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies like statins and fibrates are used to treat cardiovascular diseases, then lipid and lipoprotein levels are modulated, but they fail to effectively reduce triglyceride levels and cause significant side effects when used in combination
Solution Approach 1:
The patent employs a composite lipid formulation consisting of multiple lipid types (triglycerides, phospholipids, cholesterol, and plant sterols) in specific ratios to create a synergistic therapeutic effect. This composite approach allows the composition to simultaneously address multiple lipid parameters including triglycerides, cholesterol, and lipoprotein levels, thereby achieving broader efficacy than single-therapy approaches while reducing the need for combination therapies that cause side effects
Solution Approach 2:
The patent utilizes controlled parameter changes in the form of specific lipid ratios and concentrations within the oral composition. By adjusting the proportions of different lipid components and their physical states (solid vs. liquid at room temperature), the formulation optimizes triglyceride reduction while maintaining safety margins to avoid side effects associated with conventional therapies
2Reliability
If solid solution pharmaceutical compositions are developed with multiple lipid components, then targeted delivery to macrophages and dendritic cells is achieved, but the formulation complexity increases
Solution Approach 1:
The patent employs lipid particles as intermediary carriers that naturally target macrophages and dendritic cells through their lipid composition and structure. These lipid particles act as mediators that facilitate the delivery of therapeutic compounds to specific cell types without requiring complex targeting mechanisms, thereby achieving targeted delivery while maintaining formulation simplicity
Solution Approach 2:
The patent creates a homogeneous solid solution formulation where multiple lipid components are uniformly distributed at the molecular level. This homogeneity ensures consistent delivery properties and simplifies manufacturing compared to heterogeneous formulations, reducing formulation complexity while maintaining targeted delivery effectiveness
Data Source
AI summary
The present specification discloses solid solution pharmaceutical compositions comprising hard fats, liquid lipids, and one or more cannabidiols, including a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.